Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topical Product A Clear all
Completed Early Phase 1 Interventional Results available

IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus

NCT01841619
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
IVIg
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

NCT02618759
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Role of Microdialysis for the Comparison of Topical Products

NCT01592019
View directory record Official record
Conditions
Bioequivalence
Interventions
Reference, Patch location thigh, batch 1, Test, Patch location thigh, batch 2, Reference, Patch location abdomen, batch 1, Test, Patch location abdomen, batch 2
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMP

NCT00386867
View directory record Official record
Conditions
Abortion, Induced
Interventions
800 mcg misoprostol via oral or buccal administration
Drug
Lead sponsor
Gynuity Health Projects
Other
Eligibility
18 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2007 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

NCT06357221
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Cetaphil
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Columbus, Georgia • Douglasville, Georgia • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 1 Interventional

A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract

NCT01630798
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
GI heptapeptide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 29, 2026, 3:17 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Topical CBD Cream for Degenerative Hallux Disorders

NCT04103814
View directory record Official record
Conditions
Hallux Valgus, Hallux Rigidus
Interventions
magnesium-cannabidiolic acid cream, Placebo cream
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Endpoint Study of Ivermectin 0.5% Lotion

NCT03301649
View directory record Official record
Conditions
Head Lice
Interventions
Generic Ivermectin Lotion 0.5%, Sklice® (Ivermectin) Lotion 0.5%, Vehicle Lotion
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
6 Months and older
Enrollment
905 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage

NCT03302559
View directory record Official record
Conditions
Skin Care
Interventions
Retinol Complex 0.5, Facial cleanser, Moisturizing lotion, Sunscreen, Skin Imaging
Other · Device
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT03142451
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
54
States / cities
Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

NCT02933866
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
DSXS topical, Vehicle topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

NCT04484337
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical Non-steroidal anti-inflammatory drug (NSAID), Topical steroid, Topical NSAID placebo, Recombinant human hyaluronidase PH20 (rHuPH20), Topical steroid placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 29, 2026, 3:17 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol

NCT03563365
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Replenix Power of 3 Cream with resveratrol, Adapalene and Benzoyl peroxide gel, 0.1%/2.5%
Other · Drug
Lead sponsor
Yardley Dermatology Associates
Other
Eligibility
12 Years to 40 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Yardley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)

NCT03889886
View directory record Official record
Conditions
Dry Eye
Interventions
SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%), Vehicle
Drug
Lead sponsor
Silk Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
26
States / cities
Azusa, California • Garden Grove, California • Mission Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 29, 2026, 3:17 AM EDT
Recruiting Not applicable Interventional

StrataCTX® as a Steroid Sparing Device

NCT04087629
View directory record Official record
Conditions
CTCL
Interventions
StrataCTX® gel
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791
View directory record Official record
Conditions
Rosacea
Interventions
Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam, Cleanser, Sunscreen, Towel, Moisturizing Lotion
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Encino, California • La Mesa, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis

NCT03022903
View directory record Official record
Conditions
Toenail Onychomycosis, Distal and Lateral Subungual Toenail Onychomycosis
Interventions
Aminolevulinic Acid (ALA)
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 2 Interventional

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

NCT03065556
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Solution, Vehicle Solution
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 29, 2026, 3:17 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis

NCT04033562
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Use, Opioid Dependence, Opioid Abuse, Medication Assisted Treatment, Infusion Catheter, Wound, Lidopatch, Ambu ACTion, Pregnancy Related, Cesarean Section
Interventions
Lidocaine patch, Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr
Drug · Device
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery

NCT02562924
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyposis
Interventions
MEDIHONEY®, Budesonide, Normal saline sinus rinse, Prednisone, Endoscopic sinus surgery, nasal saline spray
Device · Drug · Procedure
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Topical and Oral Regimen for Skin Health

NCT04872946
View directory record Official record
Conditions
Skin Abnormalities
Interventions
Tea, Serum, Moisturizer
Dietary Supplement · Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 29, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin as a Decolonizing Agent for MRSA

NCT03304873
View directory record Official record
Conditions
MRSA
Interventions
Retapamulin, Placebo Ointment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
9 Months to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 29, 2026, 3:17 AM EDT